CMMB Profile
Chemomab Therapeutics Ltd., based in Tel Aviv, Israel, operates as a dynamic clinical-stage biotechnology firm specializing in the discovery and development of innovative therapeutics targeting inflammation and fibrosis. Founded in 2011 as Anchiano Therapeutics Ltd. and rebranded in March 2021, the company focuses on addressing critical unmet medical needs through its pioneering approach to monoclonal antibody therapies.
At the forefront of Chemomab's pipeline is CM-101, its lead clinical product candidate. CM-101 is a humanized monoclonal antibody specifically designed to inhibit the biological activity of soluble chemokine CCL24. This therapeutic strategy holds significant promise for treating debilitating conditions such as primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc), where inflammation and fibrosis play pivotal roles in disease progression.
Beyond CM-101, Chemomab Therapeutics is committed to advancing a robust portfolio of novel biologic therapies aimed at targeting key pathways involved in chronic inflammatory diseases. The company leverages advanced research methodologies and strategic collaborations to accelerate the development of potential breakthrough treatments that could transform patient outcomes and quality of life.
With a strong foundation in scientific research and a dedicated team of experts, Chemomab Therapeutics continues to expand its capabilities in biopharmaceutical innovation. The company's strategic location in Tel Aviv, a hub of biomedical research and development, facilitates collaboration with leading academic institutions and biotechnology partners, enhancing its ability to pioneer new therapies that address the evolving challenges of inflammatory and fibrotic diseases worldwide.
|
